Risperidone drug formulations

Hypotension has been associated with risperidone (see Drug formulations below). 

Drug formulations Long-acting injectable risperidone is commonly used in patients with psychoses. There have been two studies sponsored by Janssen Cilag, the risperidone marketing authorization holder. In the first, an observational study in 842 individuals (mean age 41 years), 27% had withdrawn after 6 months because of adverse events (mean dose at end-point 36 mg) [129 ]. 

Stroke is a matter of increasing concern with some antipsychotic drugs, and the Canadian Medicine Agency has issued a warning that there is a risk of stroke with risperidone (116). On April 2005, the FDA issued an alert and asked the company to add the following information to both the oral and depot formulations The FDA has found that older patients treated with atypical neuroleptic drugs for dementia had a higher chance for death than patients who did not take the medicine. This is not an approved use (117). In some countries, the use of... 

---